One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugs

[1]  I. Kötter.  [EULAR recommendations for the management of Behçet's disease. Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)]. , 2009, Zeitschrift fur Rheumatologie.

[2]  M. Tariq,et al.  Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial , 2008, Rheumatology International.

[3]  I. Olivieri,et al.  Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature. , 2008, Arthritis and rheumatism.

[4]  A. Silman,et al.  EULAR recommendations for the management of Behçet disease , 2008, Annals of the rheumatic diseases.

[5]  B Combe,et al.  EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[6]  I. Olivieri,et al.  New approaches in the treatment of Adamantiades-Behçet's disease , 2006, Current opinion in rheumatology.

[7]  Douglas A Jabs,et al.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. , 2005, American journal of ophthalmology.

[8]  M. Todaro,et al.  NF-kappaB protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. , 2005, Arthritis and rheumatism.

[9]  Andrew D. Dick,et al.  The standardization of uveitis nomenclature (SUN) working group; standardization of uveitis nomenclature for reporting clinical data: Results of the first international workshop , 2005 .

[10]  F. Dieli,et al.  Vγ9/Vδ2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor β1 expression in active disease , 2003, Arthritis research & therapy.

[11]  Y. Hasegawa,et al.  Cytotoxic T-Cell Lymphoma Arising in Behçet Disease , 2003, International journal of hematology.

[12]  A. Tuttolomondo,et al.  Anti-tumour necrosis factor α monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet’s syndrome , 2003, Annals of the rheumatic diseases.

[13]  A. Tennant,et al.  The Behçet's disease activity index. , 2003, Advances in experimental medicine and biology.

[14]  A. Ferrante,et al.  Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease , 2002, Annals of the rheumatic diseases.

[15]  F. Dieli,et al.  Humoral and cell mediated immune response to cow's milk proteins in Behçet's disease , 2002, Annals of the rheumatic diseases.

[16]  R. Caspi.  TH1 AND TH2 RESPONSES IN PATHOGENESIS AND REGULATION OF EXPERIMENTAL AUTOIMMUNE UVEORETINITIS , 2002, International reviews of immunology.

[17]  D. McGovern,et al.  Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor α antibody , 2001, Gut.

[18]  P. Theodossiadis,et al.  Effect of infliximab on sight-threatening panuveitis in Behcet's disease , 2001, The Lancet.

[19]  F. Breedveld,et al.  Remission of Behçet's syndrome with tumour necrosis factor α blocking therapy , 2001 .

[20]  E. Vasiliauskas,et al.  Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. , 2001, Gastroenterology.

[21]  O. Ozcebe,et al.  Behçet's disease. , 2019, The New England journal of medicine.

[22]  F. Dammacco,et al.  Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12. , 1999, Arthritis and rheumatism.

[23]  A. Silman,et al.  Behçet's disease: evaluation of a new instrument to measure clinical activity. , 1999, Rheumatology.

[24]  H. Gollnick,et al.  Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe. , 1997, Yonsei medical journal.

[25]  R. Nussenblatt.  Uveitis in Behçet's disease. , 1997, International reviews of immunology.

[26]  N. Sayınalp,et al.  Cytokines in Behçet's disease. , 1996, The Journal of rheumatology.

[27]  A. Silman,et al.  [Criteria of diagnosis of Behcet's disease]. , 1975, La Tunisie medicale.

[28]  J. Mamo.  The rate of visual loss in Behçet's disease. , 1970, Archives of ophthalmology.

[29]  J. Kilburn.  EPIDEMIC ERYSIPELAS.: ITS PROGRESS, CONTAGION, CHARACTER, AND TREATMENT , 1837 .